Exagen Inc. Files 8-K on Shareholder Vote Matters
Ticker: XGN · Form: 8-K · Filed: Jun 11, 2024 · CIK: 1274737
| Field | Detail |
|---|---|
| Company | Exagen Inc. (XGN) |
| Form Type | 8-K |
| Filed Date | Jun 11, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-vote, corporate-governance
TL;DR
EXAGEN had a shareholder vote on June 10th. Details to follow.
AI Summary
Exagen Inc. filed an 8-K on June 11, 2024, reporting on a submission of matters to a vote of security holders that occurred on June 10, 2024. The company, formerly known as Exagen Diagnostics Inc., is incorporated in Delaware and headquartered in Vista, California.
Why It Matters
This filing indicates that Exagen Inc. has held or is holding a shareholder vote, which could pertain to significant corporate decisions such as board elections, mergers, or other strategic initiatives.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a shareholder vote, not an immediate financial event or significant change.
Key Players & Entities
- EXAGEN INC. (company) — Registrant
- Exagen Diagnostics Inc. (company) — Former Company Name
- June 10, 2024 (date) — Date of earliest event reported
- June 11, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Vista, CA (location) — Principal Executive Offices
FAQ
What specific matters were submitted for a vote of security holders on June 10, 2024?
The filing states that the 8-K is for the 'Submission of Matters to a Vote of Security Holders' but does not detail the specific matters in the provided text.
When was Exagen Inc. formerly known as Exagen Diagnostics Inc.?
The date of the name change from Exagen Diagnostics Inc. to Exagen Inc. was December 30, 2003.
What is Exagen Inc.'s principal executive office address?
Exagen Inc.'s principal executive offices are located at 1261 Liberty Way, Vista, CA 92081.
What is the SEC file number for Exagen Inc.?
Exagen Inc.'s SEC file number is 001-39049.
Under which section of the Securities Exchange Act of 1934 is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 534 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-06-11 16:08:13
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share XGN The Nasdaq Global Mar
Filing Documents
- exdx-20240610.htm (8-K) — 32KB
- 0001274737-24-000056.txt ( ) — 156KB
- exdx-20240610.xsd (EX-101.SCH) — 2KB
- exdx-20240610_lab.xml (EX-101.LAB) — 22KB
- exdx-20240610_pre.xml (EX-101.PRE) — 13KB
- exdx-20240610_htm.xml (XML) — 3KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. Exagen Inc. (the "Company") held its 2024 annual meeting of stockholders (the "Annual Meeting") on June 10, 2024. At the Annual Meeting, the Company's stockholders voted on two proposals, as described below. Each of the proposals was described in detail in the Company's definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 26, 2024. The vote totals noted below are final voting results from the Annual Meeting. Proposal 1 The Company's stockholders elected the following three Class II directors for a three-year term of office expiring at the Company's 2027 annual meeting of stockholders and until their successors are duly elected and qualified or until such director's earlier death, resignation or removal. Name Votes For Votes Withheld Broker Non-Votes Ana Hooker 7,720,706 338,816 3,839,742 Paul Kim 8,037,137 22,385 3,839,742 Frank Stokes 7,970,534 88,988 3,839,742 Proposal 2 The Company's stockholders ratified the appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. Votes For Votes Against Abstentions Broker Non-Votes 11,798,192 19,271 81,801 —
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EXAGEN INC. Date: June 11, 2024 By: /s/ Kamal Adawi Kamal Adawi Chief Financial Officer